FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379522763> ?p ?o ?g. }

• W4379522763 endingPage "275" @default.
• W4379522763 startingPage "274.2" @default.
• W4379522763 abstract "Background Pregnancy complications in obstetric APS (OAPS) include recurrent early pregnancy loss, fetal death, or premature birth due to preeclampsia, intrauterine growth restriction or placental insufficiency. The standard of care (SC) with low dose aspirin (LDA) and heparin has dramatically improved obstetric results, however 20-30% still have adverse outcomes despite treatment. Retrospective studies have shown good results with the addition of Hydroxychloroquine (HCQ). HCQ may have a beneficial effect in APS due to its anti-inflammatory, immunomodulatory and antithrombotic properties. Recently, EULAR recommended its use in refractory cases. Previously, in a retrospective study we reported that the addition of HCQ in women with primary OAPS and a pregnancy failure with SC was associated with a higher rate of live births (97 vs 62%) and a lower frequency of pregnancy complications (8 vs 37%) compared with conventional treatment. In this new study we show obstetric results from a larger cohort of refractory OAPS patients treated with HCQ. Objectives To assess pregnancy outcomes in a large cohort of women with refractory OAPS treated with Hydroxychloroquine in addition to conventional treatment. Methods This was an observational, retrospective, single-center cohort study. We analyzed pregnancy outcomes in women with refractory primary OAPS (2004-2022) who received HCQ 400 mg + enoxaparin 60 mg + LDA in their subsequent pregnancies. Results We evaluated 182 pregnancies in one hundred and seventy- three women (21-51y) treated with the addition of HCQ and a previous failure with conventional treatment; 18,9% of them had triple antibodies positivity. Live birth rate was 94% (CI 95%: 89,5-96,5). Term deliveries occurred in 95% of the pregnancies, mean gestational age at birth was 38 weeks (28-39) and mean weight 3021g (915g-4300g). Sixty percent were cesarean sections and 40 % vaginal deliveries. Pregnancy complications occurred in 12 % of the pregnancies (CI 95%: 7,3-19,5). Early pregnancy losses before 10 weeks occurred in 6% of the pregnancies. There were no late fetal deaths. Six patients who presented mild cutaneous allergy had to interrupt HCQ and were excluded from the analysis. Conclusion These results add observational evidence in favor of using Hydroxychloroquine in refractory Obstetric APS patients until results from ongoing RCT are published. References [1]Tektonidou MG et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis 2019 Oct;78(10):1296-1304. [2]Alijotas-Reig J et al. Pathogenesis, Diagnosis and Management of Obstetric Antiphospholipid Syndrome: A Comprehensive Review. J Clin Med 2022 Jan 28;11(3):675. [3]Gerde M et al. The impact of hydroxychloroquine on obstetric outcomes in refractory obstetric antiphospholipid syndrome. Thromb Res. 2021; 206:104-110. [4]Sciascia S et al. The efficacy of hydroxychloroquine in altering pregnancy outcome in women with antiphospholipid antibodies. Evidence and clinical judgment. Thromb. Haemost. 2016; 115: 285–290. [5]Ruffatti A et al. The efficacy and safety of second-line treatments of refractory and/or high risk pregnant antiphospholipid syndrome patients. A systematic literature review analyzing 313 pregnancies. Semin. Arthritis Rheum. 2021; 51: 28–35. Acknowledgements: NIL. Disclosure of Interests None Declared." @default.
• W4379522763 created "2023-06-07" @default.
• W4379522763 creator A5010815653 @default.
• W4379522763 creator A5049721935 @default.
• W4379522763 creator A5049864441 @default.
• W4379522763 creator A5064892603 @default.
• W4379522763 creator A5074261351 @default.
• W4379522763 creator A5077683252 @default.
• W4379522763 date "2023-05-30" @default.
• W4379522763 modified "2023-10-05" @default.
• W4379522763 title "POS0118 ADDING HYDROXYCHLOROQUINE IN REFRACTORY OBSTETRIC APS: OBSTETRIC OUTCOMES IN 182 PREGNANCIES" @default.
• W4379522763 doi "https://doi.org/10.1136/annrheumdis-2023-eular.3389" @default.
• W4379522763 hasPublicationYear "2023" @default.
• W4379522763 type Work @default.
• W4379522763 citedByCount "0" @default.
• W4379522763 crossrefType "journal-article" @default.
• W4379522763 hasAuthorship W4379522763A5010815653 @default.
• W4379522763 hasAuthorship W4379522763A5049721935 @default.
• W4379522763 hasAuthorship W4379522763A5049864441 @default.
• W4379522763 hasAuthorship W4379522763A5064892603 @default.
• W4379522763 hasAuthorship W4379522763A5074261351 @default.
• W4379522763 hasAuthorship W4379522763A5077683252 @default.
• W4379522763 hasBestOaLocation W43795227631 @default.
• W4379522763 hasConcept C126322002 @default.
• W4379522763 hasConcept C131872663 @default.
• W4379522763 hasConcept C167135981 @default.
• W4379522763 hasConcept C2776874634 @default.
• W4379522763 hasConcept C2777218350 @default.
• W4379522763 hasConcept C2778279030 @default.
• W4379522763 hasConcept C2779123688 @default.
• W4379522763 hasConcept C2779134260 @default.
• W4379522763 hasConcept C2779234561 @default.
• W4379522763 hasConcept C2780868729 @default.
• W4379522763 hasConcept C3008058167 @default.
• W4379522763 hasConcept C524204448 @default.
• W4379522763 hasConcept C54355233 @default.
• W4379522763 hasConcept C71924100 @default.
• W4379522763 hasConcept C72563966 @default.
• W4379522763 hasConcept C86803240 @default.
• W4379522763 hasConceptScore W4379522763C126322002 @default.
• W4379522763 hasConceptScore W4379522763C131872663 @default.
• W4379522763 hasConceptScore W4379522763C167135981 @default.
• W4379522763 hasConceptScore W4379522763C2776874634 @default.
• W4379522763 hasConceptScore W4379522763C2777218350 @default.
• W4379522763 hasConceptScore W4379522763C2778279030 @default.
• W4379522763 hasConceptScore W4379522763C2779123688 @default.
• W4379522763 hasConceptScore W4379522763C2779134260 @default.
• W4379522763 hasConceptScore W4379522763C2779234561 @default.
• W4379522763 hasConceptScore W4379522763C2780868729 @default.
• W4379522763 hasConceptScore W4379522763C3008058167 @default.
• W4379522763 hasConceptScore W4379522763C524204448 @default.
• W4379522763 hasConceptScore W4379522763C54355233 @default.
• W4379522763 hasConceptScore W4379522763C71924100 @default.
• W4379522763 hasConceptScore W4379522763C72563966 @default.
• W4379522763 hasConceptScore W4379522763C86803240 @default.
• W4379522763 hasIssue "Suppl 1" @default.
• W4379522763 hasLocation W43795227631 @default.
• W4379522763 hasOpenAccess W4379522763 @default.
• W4379522763 hasPrimaryLocation W43795227631 @default.
• W4379522763 hasRelatedWork W2068265433 @default.
• W4379522763 hasRelatedWork W2097402525 @default.
• W4379522763 hasRelatedWork W2162982134 @default.
• W4379522763 hasRelatedWork W2520571625 @default.
• W4379522763 hasRelatedWork W3027791452 @default.
• W4379522763 hasRelatedWork W3110506613 @default.
• W4379522763 hasRelatedWork W3124402827 @default.
• W4379522763 hasRelatedWork W3149354770 @default.
• W4379522763 hasRelatedWork W3153679424 @default.
• W4379522763 hasRelatedWork W55816785 @default.
• W4379522763 hasVolume "82" @default.
• W4379522763 isParatext "false" @default.
• W4379522763 isRetracted "false" @default.
• W4379522763 workType "article" @default.